Syndecan-4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes

被引：27

作者：

Das, Subhamoy ^{[1
]}

Monteforte, Anthony J. ^{[1
]}

Singh, Gunjan ^{[1
]}

Majid, Marjan ^{[1
]}

Sherman, Michael B. ^{[2
]}

Dunn, Andrew K. ^{[1
]}

Baker, Aaron B. ^{[1
,3
,4
,5
]}

机构：

[1] Univ Texas Austin, Dept Biomed Engn, Austin, TX USA

[2] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA

[3] Univ Texas Austin, Inst Cellular & Mol Biol, Austin, TX 78712 USA

[4] Univ Texas Austin, Inst Computat Engn & Sci, Austin, TX 78712 USA

[5] Univ Texas Austin, Inst Biomat Drug Delivery & Regenerat Med, Austin, TX 78712 USA

来源：

ADVANCED HEALTHCARE MATERIALS | 2016年 / 5卷 / 09期

关键词：

PERIPHERAL ARTERIAL-DISEASE; FIBROBLAST GROWTH FACTOR-2; INTERMITTENT CLAUDICATION; DOUBLE-BLIND; TRIAL; PLACEBO;

D O I：

10.1002/adhm.201500993

中图分类号：

R318 [生物医学工程];

学科分类号：

0831 ;

摘要：

Delivering syndecan-4 with FGF-2 improves the effectiveness of FGF-2 therapy for ischemia in the diabetic disease state. The syndecan-4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan-4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype. © 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

引用

收藏

页码：1008 / 1013

页数：6

相关论文

共 20 条

[1] Economic Costs of Diabetes in the U.S. in 2012 [J].

Yang W. ;

Dall T.M. ;

Halder P. ;

Gallo P. ;

Kowal S.L. ;

Hogan P.F. ;

Petersen M. .

DIABETES CARE, 2013, 36 (04) :1033-1046

[2]

Bruhn-Olszewska B, 2012, ACTA BIOCHIM POL, V59, P507

[3] Overcoming disease-induced growth factor resistance in therapeutic angiogenesis using recombinant co-receptors delivered by a liposomal system [J].

Das, Subhamoy ;

Singh, Gunjan ;

Baker, Aaron B. .

BIOMATERIALS, 2014, 35 (01) :196-205

[4] Syndecan-4 signaling at a glance [J].

Elfenbein, Arye ;

Simons, Michael .

JOURNAL OF CELL SCIENCE, 2013, 126 (17) :3799-3804

[5] Syndecan-4 proteoliposomes enhance fibroblast growth factor-2 (FGF-2)-induced proliferation, migration, and neovascularization of ischemic muscle [J].

Jang, Eugene ;

Albadawi, Hassan ;

Watkins, Michael T. ;

Edelman, Elazer R. ;

Baker, Aaron B. .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (05) :1679-1684

[6] Inflammation and wound healing: the role of the macrophage [J].

Koh, Timothy J. ;

DiPietro, Luisa Ann .

EXPERT REVIEWS IN MOLECULAR MEDICINE, 2011, 13 :e23

[7] Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: A double-blind randomized trial [J].

Kusumanto, Y. H. ;

Van Weel, V. ;

Mulder, N. H. ;

Smit, A. J. ;

Van den Dungen, J. J. A. M. ;

Hooymans, J. M. M. ;

Sluiter, W. J. ;

Tio, R. A. ;

Quax, P. H. A. ;

Gans, R. O. B. ;

Dullaart, R. P. F. ;

Hospers, G. A. P. .

HUMAN GENE THERAPY, 2006, 17 (06) :683-691

[8] Basic fibroblast growth factor in patients with intermittent claudication: Results of a phase I trial [J].

Lazarous, DF ;

Unger, EF ;

Epstein, SE ;

Stine, A ;

Arevalo, JL ;

Chew, EY ;

Quyyumi, AA .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (04) :1239-1244

[9] Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial [J].

Lederman, RJ ;

Mendelsohn, FO ;

Anderson, RD ;

Saucedo, JF ;

Tenaglia, AN ;

Hermiller, JB ;

Hillegass, WB ;

Rocha-Singh, K ;

Moon, TE ;

Whitehouse, MJ ;

Annex, BH .

LANCET, 2002, 359 (9323) :2053-2058

[10] Peripheral arterial disease in patients with diabetes [J].

Marso, SP ;

Hiatt, WR .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (05) :921-929